Alnylam Pharmaceuticals Inc (ALNY)

Jan 21, 2025

Assenagon Asset Management S.A. Acquires 2,285 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Jan 21, 2025

Jan 21, 2025

Royal Bank of Canada Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

Jan 21, 2025

Jan 21, 2025

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? - Yahoo Finance

Jan 21, 2025

Jan 20, 2025

Hemophilia B Market to Show Remarkable Growth Trends from 2024 - openPR

Jan 20, 2025

Jan 18, 2025

Gateway Investment Advisers LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Jan 18, 2025

Jan 17, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7%Here's What Happened - MarketBeat

Jan 17, 2025

Jan 17, 2025

Empirical Asset Management LLC Takes $12.15 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Jan 17, 2025

Jan 17, 2025

FY2024 Earnings Forecast for ALNY Issued By Zacks Research - MarketBeat

Jan 17, 2025

Jan 17, 2025

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment? - Simply Wall St

Jan 17, 2025

Jan 15, 2025

Burney Co. Buys 4,791 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Jan 15, 2025

Jan 15, 2025

What is William Blair's Estimate for ALNY FY2024 Earnings? - MarketBeat

Jan 15, 2025

Jan 13, 2025

Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters ATTR-CM stock outlook - Investing.com

Jan 13, 2025

Jan 13, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 7.1%Still a Buy? - MarketBeat

Jan 13, 2025

Jan 13, 2025

Alnylam Shares Rise 8% On Preliminary Product Revenue Growth - MarketWatch

Jan 13, 2025

Jan 13, 2025

Alnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 13, 2025

Jan 13, 2025

Alnylam shares jump on strong revenue forecast and profit outlook By Investing.com - Investing.com Australia

Jan 13, 2025

Jan 13, 2025

Alnylam shares jump on strong revenue forecast and profit outlook - Investing.com

Jan 13, 2025

Jan 13, 2025

ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - Yahoo Finance

Jan 13, 2025

Jan 13, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat

Jan 13, 2025

Jan 13, 2025

What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga

Jan 13, 2025

Jan 13, 2025

Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y (NASDAQ:ALNY) - Seeking Alpha

Jan 13, 2025

Jan 13, 2025

Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR

Jan 13, 2025

Jan 12, 2025

Alnylam Reports Strong 33% Growth, Sets Ambitious $2.25B Revenue Target for 2025 - StockTitan

Jan 12, 2025

Jan 12, 2025

Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 -January 12, 2025 at 04:00 pm EST - Marketscreener.com

Jan 12, 2025

Jan 11, 2025

Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals - MSN

Jan 11, 2025

Jan 10, 2025

Bausch + Lomb taps ex-Alnylam team's new venture for RNA eye disease programme - FirstWord Pharma

Jan 10, 2025

Jan 09, 2025

StockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold - MarketBeat

Jan 09, 2025

Jan 09, 2025

Alpha-1 Antitrypsin Deficiency Clinical and Non-Clinical - openPR

Jan 09, 2025

Jan 07, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $310.00 at Sanford C. Bernstein - MarketBeat

Jan 07, 2025

Jan 07, 2025

City Therapeutics Appoints Andy Orth as Chief Executive Officer - BioSpace

Jan 07, 2025

Jan 07, 2025

Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025 - Seeking Alpha

Jan 07, 2025

Jan 06, 2025

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Jan 06, 2025

Jan 06, 2025

5 FDA decisions to watch in the first quarter of 2025 - BioPharma Dive

Jan 06, 2025

Jan 06, 2025

5 FDA Decisions to Watch in Q1 - BioSpace

Jan 06, 2025

Jan 05, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jan 05, 2025

Jan 05, 2025

2,520 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Everence Capital Management Inc. - MarketBeat

Jan 05, 2025

Jan 04, 2025

Principal Financial Group Inc. Has $2.92 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Jan 04, 2025

Jan 02, 2025

When the Price of (ALNY) Talks, People Listen - Stock Traders Daily

Jan 02, 2025

Dec 27, 2024

Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Buy at StockNews.com - MarketBeat

Dec 27, 2024

Dec 26, 2024

Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St

Dec 26, 2024

Dec 26, 2024

Dyslipidemia Market Poised for Significant Growth from 2024 - openPR

Dec 26, 2024

Dec 25, 2024

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? - MSN

Dec 25, 2024

Dec 24, 2024

How Is The Market Feeling About Alnylam Pharmaceuticals? - Benzinga

Dec 24, 2024

Dec 23, 2024

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? - Insider Monkey

Dec 23, 2024

Dec 23, 2024

When (ALNY) Moves Investors should Listen - Stock Traders Daily

Dec 23, 2024

Dec 21, 2024

Sanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Dec 21, 2024

Dec 20, 2024

City: Taking RNAi beyond the liver - BioCentury

Dec 20, 2024

Dec 20, 2024

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

4 Biotech Stocks Most Wall Street Analysts Are Bullish About - Yahoo Finance

Dec 19, 2024

Dec 19, 2024

Biotech CEO on RNAI and Medicine of the Future - Barron's

Dec 19, 2024